As of 2024-12-12, the Intrinsic Value of Eagle Pharmaceuticals Inc (EGRX) is
115.19 USD. This EGRX valuation is based on the model Discounted Cash Flows (Growth Exit 5Y).
With the current market price of 2.14 USD, the upside of Eagle Pharmaceuticals Inc is
5,282.90%.
The range of the Intrinsic Value is 94.36 - 148.12 USD
115.19 USD
Intrinsic Value
EGRX Intrinsic Value - Valuation Summary
|
Range |
Selected |
Upside |
| a |
| DCF (Growth 5y) |
94.36 - 148.12 |
115.19 |
5282.9% |
| DCF (Growth 10y) |
106.94 - 162.43 |
128.53 |
5905.9% |
| DCF (EBITDA 5y) |
119.10 - 167.66 |
136.68 |
6286.7% |
| DCF (EBITDA 10y) |
125.71 - 176.73 |
144.72 |
6662.6% |
| Fair Value |
58.64 - 58.64 |
58.64 |
2,640.30% |
| P/E |
58.31 - 179.25 |
120.43 |
5527.8% |
| EV/EBITDA |
169.96 - 289.67 |
234.18 |
10843.2% |
| EPV |
85.68 - 112.27 |
98.98 |
4525.1% |
| DDM - Stable |
6.15 - 11.93 |
9.04 |
322.3% |
| DDM - Multi |
10.91 - 18.18 |
13.76 |
543.0% |
EGRX Intrinsic Value - Key Valuation Metrics
| Market Cap (mil) |
11.04 |
| Beta |
3.73 |
| Outstanding shares (mil) |
5.16 |
| Enterprise Value (mil) |
65.84 |
| Market risk premium |
4.60% |
| Cost of Equity |
22.71% |
| Cost of Debt |
5.00% |
| WACC |
5.88% |